Global /United States /Healthcare /Medical Devices /HAE
chevron_leftBack

Haemonetics Corp.

HAE
NYSE: HAE Delayed
60.34USD 2%
As of 24 April 2025, Haemonetics Corp. has a market cap of $3.03B USD, ranking #4087 globally and #1213 in the United States. It ranks #349 in the Healthcare sector, and #40 in the Medical Devices industry.
Global Rank
4087
Country Rank
1213
Sector Rank
349
Industry Rank
40
Key Stats
Market Cap
$3.03BUSD
Enterprise Value
$4.0BUSD
Revenue (TTM)
$1.37BUSD
EBITDA (TTM)
$346.06MUSD
Net Income (TTM)
$130.07MUSD
EBITDA Margin
25%
Profit Margin
9.5%
PE Ratio
23.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Christopher Simon open_in_new
Employees
3,657
Founded
1971
IPO
09 May 1991
Website
haemonetics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2% 6.1% -5.7% -18% -19% -28%
Upcoming Earnings
Earnings Date
Thu, May 8
Earnings Time
sunny Before Open
EPS Estimate
$1.22 36% yoy
Revenue Estimate
$329.38M -4.1% yoy

Markets

Exchange Ticker Price
NYSE
MIC: XNYS
PRIMARY
HAE
Haemonetics Corp
ISIN: US4050241003
Shares Out.:
50.238M1 Shares Float: 49.681M2
TV:
SA:
YF:
HAE
GF:
NQ:
HAE
BA:
HAE
MS:
60.34 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Haemonetics Corp.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Similar Companies

Industry: Medical Devices (United States)
Name
Market Cap diff.
Abbott Laboratories
ABT
$225.18B
7K%
Boston Scientific Corp.
BSX
$146.31B
5K%
Stryker Corp.
SYK
$136.3B
4K%
Edwards Lifesciences Corp.
EW
$41.27B
1K%
DexCom, Inc.
DXCM
$26.22B
765%
Industry: Medical Devices (Global)
Name
Market Cap diff.
Medtronic plc
MDT
$107.41B
3K%
Siemens Healthineers AG
SHL
$57.76B
50.97B EUR
2K%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
300760
$36.05B
262.7B CNY
1K%
Koninklijke Philips N.V.
PHIA
$22.27B
19.57B EUR
635%
STERIS plc
STE
$22.0B
626%